ADMA
ADMA Biologics, Inc.
Price Chart
Latest Quote
$17.50
Current Price| Previous Close | $17.30 |
| Open | $17.14 |
| Day High | $17.61 |
| Day Low | $17.06 |
| Volume | 1,880,998 |
Stock Information
| Shares Outstanding | 238.00M |
| Total Debt | $83.12M |
| Cash Equivalents | $61.38M |
| Revenue | $488.56M |
| Net Income | $209.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $4.18B |
| P/E Ratio | 20.35 |
| EPS (TTM) | $0.86 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 27/42| Debt to Equity | 0.24 |
| Debt to Earnings | 0.37 |
| Current Ratio | 5.97 |
| Quick Ratio | 2.76 |
| Avg Revenue Growth | 106.71% |
| Profit Margin | 46.35% |
| Return on Equity | 56.64% |
| Avg FCF Growth | -46.87% |
| FCF Yield | 2.64% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $17.50 | 1,901,845 |
| 2026-01-30 | $17.30 | 3,267,800 |
| 2026-01-29 | $17.01 | 1,609,700 |
| 2026-01-28 | $16.33 | 1,912,600 |
| 2026-01-27 | $16.58 | 1,655,600 |
| 2026-01-26 | $16.96 | 2,363,100 |
| 2026-01-23 | $16.73 | 2,412,700 |
| 2026-01-22 | $17.40 | 2,260,300 |
| 2026-01-21 | $17.36 | 1,851,100 |
| 2026-01-20 | $17.59 | 1,862,500 |
| 2026-01-16 | $17.31 | 2,186,200 |
| 2026-01-15 | $17.50 | 3,137,800 |
| 2026-01-14 | $18.28 | 1,709,900 |
| 2026-01-13 | $17.70 | 2,891,700 |
| 2026-01-12 | $17.93 | 5,542,500 |
| 2026-01-09 | $17.95 | 2,175,900 |
| 2026-01-08 | $18.07 | 2,332,400 |
| 2026-01-07 | $18.82 | 1,986,000 |
| 2026-01-06 | $18.34 | 2,406,100 |
| 2026-01-05 | $18.03 | 1,936,000 |
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
đ° Latest News
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Zacks âĸ 2026-02-02T22:50:02Z
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
Zacks âĸ 2026-01-29T14:30:03Z
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Zacks âĸ 2026-01-26T22:50:01Z
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
Zacks âĸ 2026-01-22T14:13:00Z
High Growth US Tech Stocks To Watch In January 2026
Simply Wall St. âĸ 2026-01-21T11:38:27Z
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
Zacks âĸ 2026-01-20T23:00:04Z
ADMA Biologics, Inc. (ADMA): A Bull Case Theory
Insider Monkey âĸ 2026-01-14T13:36:45Z
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks âĸ 2026-01-13T22:50:04Z
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
Zacks âĸ 2026-01-13T18:28:00Z
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
Zacks âĸ 2026-01-13T14:30:04Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $199,244,000 | $161,665,000 | $112,417,000 | $74,989,000 |
| Cost Of Revenue | $206,901,000 | $169,273,000 | $118,815,000 | $79,770,000 |
| Total Revenue | $426,454,000 | $258,215,000 | $154,080,000 | $80,943,000 |
| Operating Revenue | $426,454,000 | $258,215,000 | $154,080,000 | $80,943,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $13,930,000 | $25,027,000 | $19,279,000 | $13,057,000 |
| Total Expenses | $287,471,000 | $236,583,000 | $193,445,000 | $139,317,000 |
| Other Income Expense | $-1,436,000 | $-26,461,000 | $-7,305,000 | $-252,000 |
| Other Non Operating Income Expenses | $-193,000 | $-287,000 | $-635,000 | $-252,000 |
| Net Non Operating Interest Income Expense | $-11,833,000 | $-23,410,000 | $-19,234,000 | $-13,022,000 |
| Interest Expense Non Operating | $13,930,000 | $25,027,000 | $19,279,000 | $13,057,000 |
| Operating Expense | $80,570,000 | $67,310,000 | $74,630,000 | $59,547,000 |
| Other Operating Expenses | $4,245,000 | $4,266,000 | $17,843,000 | $12,289,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Net Interest Income | $-11,833,000 | $-23,410,000 | $-19,234,000 | $-13,022,000 |
| Interest Income | $2,097,000 | $1,617,000 | $45,000 | $35,000 |
| Normalized Income | $198,654,970 | $-2,065,000 | $-59,234,000 | $-71,648,000 |
| Net Income From Continuing And Discontinued Operation | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Total Operating Income As Reported | $138,983,000 | $21,632,000 | $-39,365,000 | $-58,374,000 |
| Net Income Common Stockholders | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Net Income | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Net Income Including Noncontrolling Interests | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Net Income Continuous Operations | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Pretax Income | $125,714,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Special Income Charges | $-1,243,000 | $-26,174,000 | $-6,670,000 | $0 |
| Interest Income Non Operating | $2,097,000 | $1,617,000 | $45,000 | $35,000 |
| Operating Income | $138,983,000 | $21,632,000 | $-39,365,000 | $-58,374,000 |
| Depreciation Amortization Depletion Income Statement | $388,000 | $724,000 | $715,000 | $715,000 |
| Depreciation And Amortization In Income Statement | $388,000 | $724,000 | $715,000 | $715,000 |
| Amortization Of Intangibles Income Statement | $388,000 | $724,000 | $715,000 | $715,000 |
| Gross Profit | $219,553,000 | $88,942,000 | $35,265,000 | $1,173,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $0.81 | $-0.13 | $-0.33 | $-0.51 |
| Basic EPS | $0.85 | $-0.13 | $-0.33 | $-0.51 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-261,030 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $148,932,000 | $31,294,000 | $-32,842,000 | $-53,095,000 |
| Total Unusual Items | $-1,243,000 | $-26,174,000 | $-6,670,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-1,243,000 | $-26,174,000 | $-6,670,000 | $0 |
| Reconciled Depreciation | $8,045,000 | $8,332,000 | $7,113,000 | $5,496,000 |
| EBITDA (Bullshit earnings) | $147,689,000 | $5,120,000 | $-39,512,000 | $-53,095,000 |
| EBIT | $139,644,000 | $-3,212,000 | $-46,625,000 | $-58,591,000 |
| Diluted Average Shares | $243,342,466 | $223,977,315 | $197,874,895 | $139,578,538 |
| Basic Average Shares | $233,084,236 | $223,977,315 | $197,874,895 | $139,578,538 |
| Diluted NI Availto Com Stockholders | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Tax Provision | $-71,959,000 | $0 | $0 | - |
| Other Special Charges | $1,243,000 | $26,174,000 | $6,670,000 | - |
| Amortization | $388,000 | $724,000 | $715,000 | $715,000 |
| Research And Development | $1,813,000 | $3,300,000 | $3,614,000 | $3,646,000 |
| Selling General And Administration | $74,124,000 | $59,020,000 | $52,458,000 | $42,897,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $345,028,000 | $131,177,000 | $147,431,000 | $135,914,289 |
| Total Assets | $488,678,000 | $329,182,000 | $348,461,000 | $276,252,724 |
| Total Non Current Assets | $157,268,000 | $72,169,000 | $78,059,000 | $67,523,413 |
| Other Non Current Assets | $5,657,000 | $4,670,000 | $4,770,000 | $4,067,404 |
| Non Current Deferred Assets | $84,280,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $84,280,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $3,990,000 | $4,029,000 | $4,543,000 | $5,258,277 |
| Other Intangible Assets | $460,000 | $499,000 | $1,013,000 | $1,728,768 |
| Current Assets | $331,410,000 | $257,013,000 | $270,402,000 | $208,729,311 |
| Other Current Assets | $8,029,000 | $5,334,000 | $5,095,000 | $4,339,245 |
| Inventory | $170,235,000 | $172,906,000 | $163,280,000 | $124,724,091 |
| Receivables | $49,999,000 | $27,421,000 | $15,505,000 | $28,576,857 |
| Accounts Receivable | $49,999,000 | $27,421,000 | $15,505,000 | $28,576,857 |
| Allowance For Doubtful Accounts Receivable | $-200,000 | $-100,000 | $-100,000 | $-200,000 |
| Gross Accounts Receivable | $50,199,000 | $27,521,000 | $15,605,000 | $28,776,857 |
| Cash Cash Equivalents And Short Term Investments | $103,147,000 | $51,352,000 | $86,522,000 | $51,089,118 |
| Cash And Cash Equivalents | $103,147,000 | $51,352,000 | $86,522,000 | $51,089,118 |
| Non Current Prepaid Assets | - | - | - | $4,067,404 |
| Prepaid Assets | - | - | - | $4,339,245 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $82,116,000 | $141,418,000 | $154,442,000 | $102,919,711 |
| Long Term Debt And Capital Lease Obligation | $80,898,000 | $140,373,000 | $153,537,000 | $102,328,627 |
| Long Term Debt | $72,337,000 | $130,594,000 | $142,833,000 | $94,866,239 |
| Current Debt And Capital Lease Obligation | $1,218,000 | $1,045,000 | $905,000 | $591,084 |
| Net Debt | - | $79,242,000 | $56,311,000 | $43,777,121 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $139,660,000 | $193,976,000 | $196,487,000 | $135,080,158 |
| Total Non Current Liabilities Net Minority Interest | $84,118,000 | $144,170,000 | $157,220,000 | $104,701,843 |
| Other Non Current Liabilities | $1,673,000 | $2,107,000 | $1,850,000 | $397,351 |
| Non Current Deferred Liabilities | $1,547,000 | $1,690,000 | $1,833,000 | $1,975,865 |
| Current Liabilities | $55,542,000 | $49,806,000 | $39,267,000 | $30,378,315 |
| Other Current Liabilities | $1,853,000 | $2,365,000 | $1,796,000 | $1,011,986 |
| Current Deferred Liabilities | $143,000 | $182,000 | $143,000 | $142,834 |
| Payables And Accrued Expenses | $52,328,000 | $46,214,000 | $36,423,000 | $28,632,411 |
| Interest Payable | $2,857,000 | $546,000 | - | - |
| Payables | $23,700,000 | $15,660,000 | $13,229,000 | $12,429,409 |
| Total Tax Payable | $3,481,000 | $0 | - | - |
| Income Tax Payable | $3,481,000 | $0 | - | - |
| Accounts Payable | $20,219,000 | $15,660,000 | $13,229,000 | $12,429,409 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $349,018,000 | $135,206,000 | $151,974,000 | $141,172,566 |
| Total Equity Gross Minority Interest | $349,018,000 | $135,206,000 | $151,974,000 | $141,172,566 |
| Stockholders Equity | $349,018,000 | $135,206,000 | $151,974,000 | $141,172,566 |
| Retained Earnings | $-308,583,000 | $-506,256,000 | $-478,017,000 | $-412,112,721 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $236,620,545 | $226,063,032 | $221,816,930 | $195,813,817 |
| Share Issued | $236,620,545 | $226,063,032 | $221,816,930 | $195,813,817 |
| Tangible Book Value | $345,028,000 | $131,177,000 | $147,431,000 | $135,914,289 |
| Invested Capital | $421,355,000 | $265,800,000 | $294,807,000 | $236,038,805 |
| Working Capital | $275,868,000 | $207,207,000 | $231,135,000 | $178,350,996 |
| Capital Lease Obligations | $9,779,000 | $10,824,000 | $11,609,000 | $8,053,472 |
| Total Capitalization | $421,355,000 | $265,800,000 | $294,807,000 | $236,038,805 |
| Additional Paid In Capital | $657,577,000 | $641,439,000 | $629,969,000 | $553,265,706 |
| Capital Stock | $24,000 | $23,000 | $22,000 | $19,581 |
| Common Stock | $24,000 | $23,000 | $22,000 | $19,581 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,547,000 | $1,690,000 | $1,833,000 | $1,975,865 |
| Long Term Capital Lease Obligation | $8,561,000 | $9,779,000 | $10,704,000 | $7,462,388 |
| Current Deferred Revenue | $143,000 | $182,000 | $143,000 | $142,834 |
| Current Capital Lease Obligation | $1,218,000 | $1,045,000 | $905,000 | $591,084 |
| Current Accrued Expenses | $28,628,000 | $30,554,000 | $23,194,000 | $16,203,002 |
| Goodwill | $3,530,000 | $3,530,000 | $3,530,000 | $3,529,509 |
| Net PPE | $63,341,000 | $63,470,000 | $68,746,000 | $58,197,732 |
| Accumulated Depreciation | $-33,552,000 | $-26,737,000 | $-19,477,000 | $-13,271,853 |
| Gross PPE | $96,893,000 | $90,207,000 | $88,223,000 | $71,469,585 |
| Leases | $21,066,000 | $20,811,000 | $17,931,000 | $11,129,639 |
| Construction In Progress | $8,149,000 | $2,273,000 | $6,727,000 | $5,496,222 |
| Other Properties | $29,939,000 | $30,728,000 | $29,253,000 | $23,965,649 |
| Machinery Furniture Equipment | $11,612,000 | $11,838,000 | $10,429,000 | $7,471,602 |
| Buildings And Improvements | $21,788,000 | $20,218,000 | $19,544,000 | $19,067,032 |
| Land And Improvements | $4,339,000 | $4,339,000 | $4,339,000 | $4,339,441 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $48,121,000 | $70,286,000 | $58,465,000 | $28,999,836 |
| Work In Process | $61,641,000 | $49,621,000 | $56,171,000 | $58,968,535 |
| Raw Materials | $60,473,000 | $52,999,000 | $48,644,000 | $36,755,720 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $110,097,000 | $3,819,000 | $-73,419,000 | $-125,880,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $118,672,000 | $8,800,000 | $-59,508,000 | $-112,369,000 |
| Cash Flow From Continuing Operating Activities | $118,672,000 | $8,800,000 | $-59,508,000 | $-112,369,000 |
| Operating Gains Losses | $1,349,000 | $26,356,000 | $7,097,000 | $221,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-8,575,000 | $-4,981,000 | $-13,911,000 | $-13,511,000 |
| Investing Cash Flow | $-8,575,000 | $-4,981,000 | $-13,911,000 | $-13,511,000 |
| Cash Flow From Continuing Investing Activities | $-8,575,000 | $-4,981,000 | $-13,911,000 | $-13,511,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $0 | $0 | $64,645,000 | $121,144,000 |
| Financing Cash Flow | $-58,302,000 | $-38,989,000 | $108,852,000 | $121,048,000 |
| Cash Flow From Continuing Financing Activities | $-58,302,000 | $-38,989,000 | $108,852,000 | $121,048,000 |
| Net Other Financing Charges | $-5,796,000 | $-16,492,000 | $-7,682,000 | $-62,000 |
| Net Common Stock Issuance | $0 | $0 | $64,645,000 | $121,144,000 |
| Common Stock Issuance | $0 | $0 | $64,645,000 | $121,144,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-60,000,000 | $-158,601,000 | $-100,036,000 | $-34,000 |
| Issuance Of Debt | $0 | $135,000,000 | $151,750,000 | $0 |
| Interest Paid Supplemental Data | $10,668,000 | $18,051,000 | $13,880,000 | $11,159,000 |
| Income Tax Paid Supplemental Data | $9,392,000 | $0 | $0 | - |
| End Cash Position | $103,147,000 | $51,352,000 | $86,522,000 | $51,089,000 |
| Beginning Cash Position | $51,352,000 | $86,522,000 | $51,089,000 | $55,921,000 |
| Changes In Cash | $51,795,000 | $-35,170,000 | $35,433,000 | $-4,832,000 |
| Proceeds From Stock Option Exercised | $7,494,000 | $1,104,000 | $175,000 | $0 |
| Net Issuance Payments Of Debt | $-60,000,000 | $-23,601,000 | $51,714,000 | $-34,000 |
| Net Long Term Debt Issuance | $-60,000,000 | $-23,601,000 | $51,714,000 | $-34,000 |
| Long Term Debt Payments | $-60,000,000 | $-158,601,000 | $-100,036,000 | $-34,000 |
| Long Term Debt Issuance | $0 | $135,000,000 | $151,750,000 | $0 |
| Net Intangibles Purchase And Sale | $-349,000 | $-210,000 | $0 | $0 |
| Purchase Of Intangibles | $-349,000 | $-210,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-8,226,000 | $-4,771,000 | $-13,911,000 | $-13,511,000 |
| Purchase Of PPE | $-8,226,000 | $-4,771,000 | $-13,911,000 | $-13,511,000 |
| Change In Working Capital | $-18,539,000 | $-10,123,000 | $-18,286,000 | $-51,680,000 |
| Change In Other Current Liabilities | $-1,144,000 | $-791,000 | $-502,000 | $219,000 |
| Change In Payables And Accrued Expense | $5,192,000 | $11,369,000 | $8,334,000 | $9,697,000 |
| Change In Accrued Expense | $1,042,000 | $7,530,000 | $7,534,000 | $8,341,000 |
| Change In Payable | $4,150,000 | $3,839,000 | $800,000 | $1,356,000 |
| Change In Account Payable | $4,150,000 | $3,839,000 | $800,000 | $1,356,000 |
| Change In Prepaid Assets | $-2,680,000 | $841,000 | $-634,000 | $-3,068,000 |
| Change In Inventory | $2,671,000 | $-9,626,000 | $-38,556,000 | $-43,188,000 |
| Change In Receivables | $-22,578,000 | $-11,916,000 | $13,072,000 | $-15,340,000 |
| Changes In Account Receivables | $-22,578,000 | $-11,916,000 | $13,072,000 | $-15,340,000 |
| Other Non Cash Items | $808,000 | $6,287,000 | $5,257,000 | $1,754,000 |
| Stock Based Compensation | $13,616,000 | $6,187,000 | $5,215,000 | $3,488,000 |
| Deferred Tax | $-84,280,000 | $0 | $0 | - |
| Deferred Income Tax | $-84,280,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $8,045,000 | $8,332,000 | $7,113,000 | $5,496,000 |
| Depreciation And Amortization | $8,045,000 | $8,332,000 | $7,113,000 | $5,496,000 |
| Gain Loss On Sale Of PPE | $106,000 | $182,000 | $427,000 | $221,000 |
| Net Income From Continuing Operations | $197,673,000 | $-28,239,000 | $-65,904,000 | $-71,648,000 |
| Sale Of PPE | - | - | - | $0 |